AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice

Life Sciences

Volumn 82, Issue 23-24, 2008, Pages 1154-1161

  Zhang, Ying ^a   Ma, Hong ^a   Zhang, Jinchun ^a   Liu, Shilian ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

AAV; Gene therapy; hTERT; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; DACTINOMYCIN; ENZYME; FLUOROURACIL; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; ENZYME BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER HISTOLOGY; LIVER METASTASIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; TRANSGENE; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; FLUOROURACIL; GENE EXPRESSION; GENE THERAPY; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 44149084623     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.03.023     Document Type: Article

References (31)

1. Armeanu S., Lauer U.M., Smirnow I., Schenk M., Weiss T.S., Gregor M., and Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Research 63 10 (2003) 2369-2372
2. Horikawa L., Cable P.L., Afshari C., and Barrett J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Research 59 4 (1999) 826-830
3. Jacob D., Davis J., Zhu H., Zhang L., Teraishi F., Wu S., Marini F.C., and Fang B. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clinical Cancer Research 10 10 (2004) 3535-3541
4. Jacob D., Davis J.J., Zhang L., Zhu H., Teraishi F., and Fang B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Therapy 12 2 (2005) 109-115
5. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Medicine 6 5 (2000) 564-567
6. Kamizono J., Nagano S., Murofushi Y., Komiya S., Fujiwara H., Matsuishi T., and Kosai K. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Research 65 12 (2005) 5284-5291
7. Kim Y., and Seol D.W. TRAIL, a might apoptosis inducer. Molecules and Cells 15 3 (2003) 283-293
8. Koga S., Hirohata S., Kondo Y., Komata T., Takakura M., Inoue M., Kyo S., and Kondo S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Human Gene Therapy 11 10 (2000) 1397-1406
9. Leverkus M., Neumann M., Mengling T., Rauch C.T., Bröcker E.B., Krammer P.H., and Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Research 60 3 (2000) 553-559
10. Lin T., Huang X., Gu J., Zhang L., Roth J.A., Xiong M., Curley S.A., Yu Y., Hunt K.K., and Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21 52 (2002) 8020-8028
11. Ma H., Liu Y., Liu S., Xu R., and Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 42 6 (2005) 1355-1363
12. Ma H., Liu Y., Liu S., Kung H.F., Sun X., Zheng D., and Xu R. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer 116 2 (2005) 314-321
13. Majumdar A.S., Hughes D.E., Lichtsteiner S.P., Wang Z., Lebkowski J.S., and Vasserot A.P. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Therapy 8 7 (2001) 568-578
14. Mitsiades C.S., Treon S.P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., and Anderson K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98 3 (2001) 795-804
15. Mohr A., Henderson G., Dudus L., Herr I., Kuerschner T., Debatin K.M., Weiher H., Fisher K.J., and Zwacka R.M. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Therapy 11 6 (2004) 534-543
16. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., and Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Research 60 4 (2005) 847-853
17. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., and Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Research 62 20 (2002) 5800-5806
18. Nesterov A., Ivashchenko Y., and Kraft A.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21 7 (2002) 1135-1140
19. Nitsch R., Bechmann I., Deisz R.A., Haas D., Lehmann T.N., Wendling U., and Zipp F. Human brain-cell death induced by tumour necrosis factor-related apoptosis-inducing ligand. Lancet 356 9232 (2000) 827-828
20. Ponnazhagan S., Mahendra G., Kumar S., Shaw D.R., Stockard C.R., Grizzle W.E., and Meleth S. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Research 64 5 (2004) 1781-1787
21. Renshaw S.A., Parmar J.S., Singleton V., Rowe S.J., Dockrell D.H., Dower S.K., Bingle C.D., Chilers E.R., and Whyte M.K. Acceleration of human neutrophil apoptosis by TRAIL. Journal of Immunology 170 2 (2003) 1027-1033
22. Shi J., Zheng D., Liu Y., Sham M.H., Tam P., Farzaneh F., and Xu R. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Research 65 5 (2005) 1687-1692
23. Song J.S. Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer. Bioscience Biotechnology Biochemistry 69 1 (2005) 56-62
24. Streck C.J., Dickson P.V., Ng C.Y., Zhou J., Gray J.T., Nathwani A.C., and Davidoff A.M. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clinical Cancer Research 11 16 (2005) 6020-6029
25. Subramanian I.V., Ghebre R., and Ramakrishnan R. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Therapy 12 1 (2005) 30-38
26. Tomizawa M., Saisho H., and Tagawa M. Regulatory regions of growth-related genes can activate an exogenous gene of the α-Fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells. Anticancer Research 23 4 (2003) 3273-3277
27. Van Houdt W.J., Haviv Y.S., Lu B., Wang M., Rivera A.A., Ulasov I.V., Lamfers M.L., Rein D., Lesniak M.S., Siegal G.P., Dirven C.M., Curiel D.T., and Zhu Z.B. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. Journal of Neurosurgery 104 4 (2006) 583-592
28. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine 5 2 (1999) 157-163
29. Wesseling J.G., Yamamoto M., Adachi Y., Bosma P.J., van Wijland M., Blackwell J.L., Li H., Reynolds P.N., Dmitriev I., Vickers S.M., Huibregtse K., and Curiel D.T. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Therapy 8 12 (2001) 990-996
30. Yamamoto M., Alemany R., Adachi Y., Grizzle W.E., and Curiel D.T. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Molecular Therapy 3 3 (2001) 385-394
31. Yamanaka T., Shiraki K., Sugimoto K., Ito T., Fujikawa K., Ito M., Takase K., Moriyama M., Nakano T., and Suzuki A. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32 3 (2000) 482-490